Gastrointestinal toxicity associated to radiation therapy

Area of Science:

• Oncology
• Radiation Oncology
• Medical Physics

Background:

• Combined modality treatments (surgery, chemotherapy, radiation therapy) improve outcomes for thoracic, abdominal, and pelvic cancers.
• Significant clinical toxicity is a challenge in combined treatment protocols.
• Emerging technologies aim to mitigate treatment-related side effects.

Purpose of the Study:

• To explore the role of advanced radiation therapy techniques in managing treatment toxicity.
• To investigate the use of dose-volume histograms (DVH) for assessing organ-at-risk radiation doses.
• To consider factors influencing treatment toxicity and explore potential preventative strategies.

Main Methods:

• Utilizing tridimensional conformal radiotherapy (3D-CRT) for precise radiation delivery.
• Generating dose-volume histograms (DVH) to quantify radiation dose to organs at risk.
• Reviewing treatment options including medical therapies, endoscopic procedures, hyperbaric oxygen, and surgery.
• Investigating pharmacological agents for preventing gastrointestinal toxicity.

Main Results:

• 3D-CRT enables detailed dose assessment for organs at risk via DVH.
• Understanding the interplay between dose, clinical, anatomical, and genetic factors is crucial.
• Various treatment modalities exist, with ongoing research into toxicity prevention.

Conclusions:

• Advanced radiation planning tools like 3D-CRT and DVH are essential for optimizing cancer treatment.
• Personalized approaches considering patient-specific factors are key to managing toxicity.
• Further research into pharmacological interventions may reduce treatment-related side effects.